[go: up one dir, main page]

WO2018178243A3 - Dihydrotetrabenazine for use in the treatment a movement disorder - Google Patents

Dihydrotetrabenazine for use in the treatment a movement disorder Download PDF

Info

Publication number
WO2018178243A3
WO2018178243A3 PCT/EP2018/058088 EP2018058088W WO2018178243A3 WO 2018178243 A3 WO2018178243 A3 WO 2018178243A3 EP 2018058088 W EP2018058088 W EP 2018058088W WO 2018178243 A3 WO2018178243 A3 WO 2018178243A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihydrotetrabenazine
treatment
movement disorder
tourette
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/058088
Other languages
French (fr)
Other versions
WO2018178243A2 (en
Inventor
Andrew John Duffield
Anant Pandya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adeptio Pharmaceuticals Ltd
Original Assignee
Adeptio Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1705304.2A external-priority patent/GB201705304D0/en
Priority claimed from GBGB1705305.9A external-priority patent/GB201705305D0/en
Priority claimed from GBGB1705306.7A external-priority patent/GB201705306D0/en
Priority to EP18718398.3A priority Critical patent/EP3606530A2/en
Application filed by Adeptio Pharmaceuticals Ltd filed Critical Adeptio Pharmaceuticals Ltd
Priority to JP2019553960A priority patent/JP7250692B2/en
Priority to RU2019134416A priority patent/RU2768738C2/en
Priority to CN201880035549.0A priority patent/CN110691596A/en
Priority to AU2018241940A priority patent/AU2018241940B2/en
Priority to CA3057548A priority patent/CA3057548A1/en
Publication of WO2018178243A2 publication Critical patent/WO2018178243A2/en
Publication of WO2018178243A3 publication Critical patent/WO2018178243A3/en
Anticipated expiration legal-status Critical
Priority to JP2022194948A priority patent/JP7595630B2/en
Priority to AU2023274089A priority patent/AU2023274089B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the use of (+)-β-dihydrotetrabenazine and combinations of (+)-α-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and/or (+)-β- dihydrotetrabenazine, for the treatment of movement disorders, such as Tourette's syndrome. The invention also provides dosage forms containing said dihydrotetrabenazine isomers.
PCT/EP2018/058088 2017-04-01 2018-03-29 Pharmaceutical compositions Ceased WO2018178243A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3057548A CA3057548A1 (en) 2017-04-01 2018-03-29 Pharmaceutical compositions
AU2018241940A AU2018241940B2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder
CN201880035549.0A CN110691596A (en) 2017-04-01 2018-03-29 pharmaceutical composition
EP18718398.3A EP3606530A2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder
JP2019553960A JP7250692B2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in treating movement disorders
RU2019134416A RU2768738C2 (en) 2017-04-01 2018-03-29 USE OF (−)-α-DIHYDROTETRABENAZINE OR A COMBINATION THEREOF WITH (+)-α-DIHYDROTETRABENAZINE IN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDER, AS WELL AS CORRESPONDING METHODS
JP2022194948A JP7595630B2 (en) 2017-04-01 2022-12-06 Dihydrotetrabenazine for use in the treatment of movement disorders
AU2023274089A AU2023274089B2 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB1705304.2 2017-04-01
GB1705305.9 2017-04-01
GBGB1705304.2A GB201705304D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GBGB1705306.7A GB201705306D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705306.7 2017-04-01
GBGB1705305.9A GB201705305D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
US201762515940P 2017-06-06 2017-06-06
US201762515930P 2017-06-06 2017-06-06
US201762515935P 2017-06-06 2017-06-06
US62/515,930 2017-06-06
US62/515,935 2017-06-06
US62/515,940 2017-06-06

Publications (2)

Publication Number Publication Date
WO2018178243A2 WO2018178243A2 (en) 2018-10-04
WO2018178243A3 true WO2018178243A3 (en) 2018-12-13

Family

ID=63674294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/058088 Ceased WO2018178243A2 (en) 2017-04-01 2018-03-29 Pharmaceutical compositions

Country Status (7)

Country Link
EP (1) EP3606530A2 (en)
JP (2) JP7250692B2 (en)
CN (1) CN110691596A (en)
AU (2) AU2018241940B2 (en)
CA (1) CA3057548A1 (en)
RU (2) RU2022104034A (en)
WO (1) WO2018178243A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190108149A (en) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 How do I administer certain VMAT2 inhibitors?
BR112020005373A2 (en) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulation of high-dose valbenazine and valbenazine-related compositions, methods and kits
CA3077149A1 (en) 2017-10-10 2019-04-18 Neurocrine Biosciences, Inc. Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
BR112020024018A2 (en) 2018-06-14 2021-02-23 Neurocrine Biosciences Inc. vmat2 inhibitor compounds, compositions and methods related to them
WO2020037022A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
AU2021362683A1 (en) * 2020-10-12 2023-06-01 Auspex Pharmaceuticals Llc Gastro retentive dosage forms comprising deutetrabenazine
KR20250057882A (en) * 2022-09-08 2025-04-29 레드엑스 파마 리미티드 ROCK inhibitor in solid form

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB800969A (en) * 1956-02-08 1958-09-03 Hoffmann La Roche Novel 2-hydroxy-benzo [ª‡] quinolizines, acid addition salts thereof and a process for the manufacture of same
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010018408A2 (en) * 2008-08-12 2010-02-18 Biovail Laboratories International (Barbados) Srl Pharmaceutical compositions
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
CN103003275A (en) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Benzoquinolinone inhibitors of VMAT2
CN102285984B (en) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 Preparation method of (2R, 3R, 11bR)-dihydrotetrabenazine and relevant compounds
HK1212232A1 (en) * 2012-09-18 2016-06-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB800969A (en) * 1956-02-08 1958-09-03 Hoffmann La Roche Novel 2-hydroxy-benzo [ª‡] quinolizines, acid addition salts thereof and a process for the manufacture of same
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2010018408A2 (en) * 2008-08-12 2010-02-18 Biovail Laboratories International (Barbados) Srl Pharmaceutical compositions
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JACK J CHEN ET AL: "Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 34, no. 7, 7 June 2012 (2012-06-07), pages 1487 - 1504, XP028405380, ISSN: 0149-2918, [retrieved on 20120620], DOI: 10.1016/J.CLINTHERA.2012.06.010 *
KARL G. BOLDT ET AL: "Synthesis of (+)- and (-)-Tetrabenazine from the Resolution of [alpha]-Dihydrotetrabenazine", SYNTHETIC COMMUNICATIONS, vol. 39, no. 20, 18 September 2009 (2009-09-18), PHILADELPHIA, PA; US, pages 3574 - 3585, XP055423935, ISSN: 0039-7911, DOI: 10.1080/00397910902788125 *
KILBOURN ET AL: "Rat pancreas uptake of [<11>C]dihydrotetrabenazine stereoisomers", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, vol. 37, no. 8, 1 November 2010 (2010-11-01), pages 869 - 871, XP027472058, ISSN: 0969-8051, [retrieved on 20100724], DOI: 10.1016/J.NUCMEDBIO.2010.06.001 *
YAO ET AL: "Preparation and evaluation of tetrabenazine enantiomers and all eight stereoismores of dihydrotetrabenazine as VMAT2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,, vol. 46, 1 January 2011 (2011-01-01), pages 1841 - 1848, XP002781076 *

Also Published As

Publication number Publication date
RU2019134416A3 (en) 2021-08-18
AU2018241940A1 (en) 2019-10-03
JP2023029975A (en) 2023-03-07
EP3606530A2 (en) 2020-02-12
JP7595630B2 (en) 2024-12-06
AU2018241940B2 (en) 2023-09-28
CA3057548A1 (en) 2018-10-04
RU2768738C2 (en) 2022-03-24
CN110691596A (en) 2020-01-14
JP7250692B2 (en) 2023-04-03
RU2019134416A (en) 2021-05-04
JP2020512987A (en) 2020-04-30
AU2023274089B2 (en) 2025-04-10
RU2022104034A (en) 2022-03-05
AU2023274089A1 (en) 2023-12-14
WO2018178243A2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX394909B (en) Use of pasteurized akkermansia for treating metabolic disorders
AU2018284960A1 (en) AADC polynucleotides for the treatment of Parkinson&#39;s disease
WO2015001504A3 (en) Antibody formulations and methods
MD20170035A2 (en) Compositions and methods of use for treating matabolic disorders
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2016073693A3 (en) Aadc polynucleotides for the treatment of parkinson&#39;s disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2016066744A3 (en) Gip agonist compounds and methods
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EP4414027A3 (en) Compounds and methods for treating neurological and cardiovascular conditions
MX2020006237A (en) Compounds for treatment of diseases related to dux4 expression.
HK1251482A1 (en) Composition and method for treating complement-mediated disease
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
MX2017006437A (en) Spiro-isoquinoline-1,4&#39;-piperidine compounds having multimodal activity against pain.
WO2016170124A3 (en) Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
AU2019254701B2 (en) MIR-181 inhibitors and uses thereof
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
MX2017006513A (en) 1,9-diazaspiro undecane compounds having multimodal activity against pain.
WO2017105881A8 (en) Deuterated compounds for treating pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18718398

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3057548

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019553960

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018241940

Country of ref document: AU

Date of ref document: 20180329

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018718398

Country of ref document: EP

Effective date: 20191104